Table 3.

Bivariate and multivariate analysis of loss to follow-up

		Bivariate analysis			Multivariate analysis
Variable	Category	OR	Confidence interval	p	aOR	Confidence interval	p
Gender	Male	1.15	0.71–1.88	0.558	–	–	–
	Female	1
Age				0.050			0.011
	≤24	5.61	0.68–45.41	0.110	13.58	1.48–62.68	0.021
	25–39	2.45	0.33–18.04	0.379	4.59	0.58–36.71	0.150
	40–54	1.68	0.22–12.92	0.618	3.00	0.36–25.05	0.310
	≥55	1			1
Provider group				0.002			0.002
	<50 patients	13.35	3.00–59.30	0.001	15.83	3.44–72.82	<0.001
	50–250 patients	1			1
	>250 patients	7.93	1.92–32.69	0.004	8.70	2.70–36.57	0.003
WHO stage				0.549	–	–	–
	I	1.81	0.68–4.85	0.233
	II	1.02	0.32–3.22	0.966
	III	1.44	0.60–3.42	0.404
	IV	1
ART status				<0.001			<0.001
	Pre-ART ineligible	30.93	13.77–69.46	<0.001	33.80	14.20–80.46	<0.001
	Pre-ART eligible	11.55	6.73–19.84	<0.001	13.51	7.71–23.68	<0.001
	On ART	1			1
TB diagnosis	No	1.05	0.63–1.76	0.830	–	–	–
	Yes	1
CD4 at baseline				0.200	–	–	–
	≤50	1
	51–200	1.51	0.68–3.34	0.301
	201–350	2.37	1.11–5.04	0.025
	351–500	1.51	0.57–3.98	0.396
	>500	1.59	0.33–7.57	0.554

aOR, adjusted odds ratio; ART, antiretroviral therapy; CD4, cluster of differentiation 4; OR, odds ratio; TB, tuberculosis.